Biopoin 유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

biopoin

teva gmbh - epoetin theta - kidney failure, chronic; anemia; cancer - drugi antianemic priprave - zdravljenje simptomatske anemije, povezane s kronično ledvično odpovedjo pri odraslih bolnikih. zdravljenje simptomatsko anemija pri odraslih bolnikov z rakom z non-mieloično malignancies, ki prejemajo kemoterapijo.

Eporatio 유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

eporatio

ratiopharm gmbh - epoetin theta - kidney failure, chronic; anemia; cancer - drugi antianemic priprave - zdravljenje simptomatske anemije, povezane s kronično ledvično odpovedjo pri odraslih bolnikih. zdravljenje simptomatsko anemija pri odraslih bolnikov z rakom z non-mieloično malignancies, ki prejemajo kemoterapijo.

NeoRecormon 유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

neorecormon

roche registration gmbh - epoetin beta - kidney failure, chronic; anemia; cancer; blood transfusion, autologous - antianemični preparati - zdravljenje simptomatsko anemija, povezanih s kronično odpovedjo ledvic (crf) pri odraslih in pediatričnih bolnikih;zdravljenje simptomatsko anemija pri odraslih bolnikih z ne-mieloično malignancies, ki prejemajo kemoterapijo, povečuje donos autologous blood od bolnikov v pre-donacija program. njegova uporaba v ta prikaz mora biti uravnotežena glede na sporočene povečano tveganje thromboembolic dogodkov. zdravljenje je treba dajati bolnikom z zmerno anemija (hb 10 - 13 g/dl [6. 21 - 8. 07 mmol/l], ni pomanjkanja železa) če krvi ohranjanje postopki, ki niso na voljo ali nezadostno ko načrtovanih večjih izbirni operacijo je potrebna velika količina krvi (4 ali več enot krvi za samice, ali 5 ali več enot za moške).

Vafseo 유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

vafseo

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - antianemični preparati - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.

Reblozyl 유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

reblozyl

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - drugi antianemic priprave - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

Evrenzo 유럽 연합 - 슬로베니아어 - EMA (European Medicines Agency)

evrenzo

astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - antianemični preparati - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).